Icatibant

(Firazyr®)

Firazyr®

Drug updated on 11/9/2023

Dosage FormInjection (subcutaneous; 10 mg/mL)
Drug ClassBradykinin B2 receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Firazyr (icatibant) Prescribing Information.2021Takeda Pharmaceuticals America, Inc. Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines